Literature DB >> 33625263

Integrated Analysis Revealed the MicroRNA-Based Prognostic Predicting Signature for Papillary Renal Cell Carcinoma.

Yu Guan1,2,3, Bijun Wang4, Tao Zhang5, Sifan Gao6, Zichuan Cao4, Meng Zhang1,2,3, Chaozhao Liang1,2,3.   

Abstract

Renal cell carcinoma (RCC) is one of the most frequently occurring tumors worldwide. Herein, we established a microRNA (miRNA) predicting signature to assess the prognosis of papillary-type RCC (PRCC) patients. miR-1293, miR-34a, miR-551b, miR-937, miR-299, and miR-3199-2 were used in building the overall survival (OS)-related signature, whereas miR-7156, miR-211, and miR-301b were used to construct the formula of recurrence-free survival (RFS) with the help of LASSO Cox regression analysis. The Kaplan-Meier and receiver operating characteristic curves indicated good discrimination and efficiency of the two signatures. Functional annotation for the downstream genes of the OS/RFS-related miRNAs exposed the potential mechanisms of PRCC. Notably, the multivariate analyses suggested that the two signatures were independent risk factors for PRCC patients and had better prognostic capacity than any other classifier. In addition, the nomogram indicated synthesis effects and showed better predictive performance than clinicopathologic features and our signatures. We validated the OS and RFS prediction formulas in clinical samples and met our expectations. Finally, we established two novel miRNA-based OS and RFS predicting signatures for PRCC, which are reliable tools for assessing the prognosis of PRCC patients.

Entities:  

Keywords:  LASSO analysis; microRNA; overall survival; papillary renal cell carcinoma; recurrence-free survival

Year:  2021        PMID: 33625263     DOI: 10.1089/dna.2019.5306

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  1 in total

1.  LINC01006 and miR-3199 Serve as Novel Markers of Poor Prognosis in Colon Cancer and Regulate Cell Proliferation, Migration and Invasion.

Authors:  Yaoqiang Wu; Bo Yu; Yaping Li; Fuxiang Yu; Zhongguo Li; Daxin Chen; Feng Jiang; Jianbo Bo; Hongwei Xue; Hongyang Lv; Haiyang Li
Journal:  Int J Gen Med       Date:  2022-02-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.